Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
SAN JOSE, Calif. - Anixa Biosciences, Inc. (NASDAQ:ANIX), a clinical-stage biotechnology company with a market capitalization of $94.7 million, announced Tuesday that the United States Patent and Trademark Office has issued a new patent for its chimeric antigen receptor T-cell (CAR-T) technology, extending protection until 2045.
The patent, U.S. Patent Number 12,384,826, covers core methods and compositions of Anixa’s CAR-T platform, which is designed to address challenges in applying CAR-T therapies to solid tumors. The technology is currently being evaluated in a clinical trial at Moffitt Cancer Center for recurrent ovarian cancer patients. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 8.89, indicating robust liquidity to support its clinical programs.
"This issued patent further strengthens our growing intellectual property portfolio and reinforces the potential of our novel CAR-T program," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, in a press release statement.
The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. According to the company, its CAR-T approach differs from other cell therapies as it uses the natural ligand of the FSHR receptor, FSH, which binds to the FSHR receptor on tumor cells instead of an antibody fragment.
Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention. In addition to its CAR-T program, the company is developing vaccines for breast and ovarian cancer in collaboration with Cleveland Clinic.
The announcement comes as companies in the immuno-oncology space continue to seek patent protection for novel approaches to cancer treatment, particularly those addressing solid tumors, which have proven challenging for existing CAR-T therapies.
In other recent news, Anixa Biosciences announced the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for Anixa’s immunogenic approach to breast cancer prevention and treatment in Canada. This development enhances Anixa’s international intellectual property portfolio, complementing existing patents in the United States and other global jurisdictions. Additionally, the United States Patent and Trademark Office will issue a new patent covering key aspects of Anixa’s breast cancer vaccine technology. This patent protects novel methods of immunizing patients using an immunogenic composition containing human α-lactalbumin protein.
Furthermore, Anixa Biosciences is set to receive another U.S. patent for its ovarian cancer vaccine technology. This patent includes claims related to methods of eliciting an immune response targeting the anti-Müllerian hormone receptor, type II (AMHR2), which is a promising target for ovarian cancer prevention and treatment. In clinical developments, Anixa has dosed the first patient in the fourth cohort of its Phase 1 clinical trial for a chimeric antigen receptor T-cell (CAR-T) therapy targeting recurrent ovarian cancer. The fourth cohort will receive a higher dosage level, with no dose-limiting toxicities observed in the previous cohort. These developments reflect Anixa’s ongoing efforts in advancing its cancer vaccine and therapy technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.